Progyny (NasdaqGS:PGNY) Q4 2025 Earnings call February 26, 2026 04:45 PM ET Company ParticipantsJames Hart - VP of Investor RelationsMark Livingston - CFOPete Anevski - CEOSarah James - Managing DirectorConference Call ParticipantsBrian Tanquilut - Equity Research AnalystConstantine Davides - Healthcare Services AnalystJailendra Singh - Managing Director and Equity Research AnalystMichael Cherny - Senior Managing Director and Senior Research AnalystPeter Warendorf - Equity Research AnalystScott Schoenhaus - ...

Progyny (NasdaqGS:PGNY) Q4 2025 Earnings call February 26, 2026 04:45 PM ET Company ParticipantsJames Hart - VP of Investor RelationsMark Livingston - CFOPete Anevski - CEOSarah James - Managing DirectorConference Call ParticipantsBrian Tanquilut - Equity Research AnalystConstantine Davides - Healthcare Services AnalystJailendra Singh - Managing Director and Equity Research AnalystMichael Cherny - Senior Managing Director and Senior Research AnalystPeter Warendorf - Equity Research AnalystScott Schoenhaus - ...

Evolent to Participate in Upcoming Investor Conferences [Accessibility Statement] Skip NavigationWASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences.A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor r ...

Key Takeaways Teladoc Health reported a Q4 adjusted loss of 14 cents, narrower than estimates and year-ago loss.TDOC saw 19% international growth and 5% Integrated Care revenue growth, boosting results.BetterHelp revenues fell 6% in Q4, with 2026 guidance projecting further declines in the segment.Teladoc Health, Inc. (TDOC) reported a fourth-quarter 2025 adjusted loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents. The company posted a loss of 28 cents in the year-a ...

Core Insights - Nearly three-quarters of healthcare executives believe their organizations will be as strong or stronger in 2026, while over half expect the overall healthcare industry to face a worse year ahead, indicating a widening confidence gap [1][7] - The demand for AI-savvy leaders is surging, with 63% of leaders prioritizing the development of a clear AI strategy, 48% focusing on clinician and staff engagement for adoption, and 41% emphasizing investment in data infrastructure [3][7] - Succession planning remains underdeveloped, with fewer than half of organizations maintaining formal succession plans for any leadership level [7] Industry Trends - The 2026 Healthcare Leadership Trends survey, conducted by B.E. Smith, gathered insights from 703 healthcare executives across various leadership levels and organizational types [2][5] - Leaders are navigating financial pressures, workforce realities, and rising expectations for innovation, with a focus on adaptable leadership that can leverage AI and technology for operational improvements [3][6] - Retention risk shows signs of cooling, but 35% of leaders considering leaving would like to do so within one year, indicating ongoing mobility concerns [7] Leadership Challenges - Attracting quality leadership candidates remains extremely or very challenging for 40% of respondents, highlighting difficulties in leadership recruiting [7] - Clinician engagement continues to lag, with leadership teams perceived as more engaged compared to physicians and nursing staff, reflecting ongoing workforce experience challenges [7] - Career advancement is a friction point, as only 21% of respondents feel they are on a promotion track, while 26% believe they must leave their employer to advance [7]

Privia Health Group (NasdaqGS:PRVA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAndrew Mok - Director of Equity ResearchDavid Larsen - Managing DirectorDavid Mountcastle - EVP and CFOJailendra Singh - Managing DirectorJenny Shen - Equity Research AssociateLisa Gill - Managing DirectorMatthew Shea - VP of Equity ResearchParth Mehrotra - CEORobert Borchert - SVP of Investor and Corporate CommunicationsRyan Halstead - Managing Director of Equity ResearchConference Call ParticipantsA ...

Privia Health Group (NasdaqGS:PRVA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAndrew Mok - Director of Equity ResearchDavid Larsen - Managing DirectorDavid Mountcastle - EVP and CFOJailendra Singh - Managing DirectorJenny Shen - Equity Research AssociateLisa Gill - Managing DirectorMatthew Shea - VP of Equity ResearchParth Mehrotra - CEORobert Borchert - SVP of Investor and Corporate CommunicationsRyan Halstead - Managing Director of Equity ResearchConference Call ParticipantsA ...

Privia Health Group (NasdaqGS:PRVA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker15Good morning, ladies and gentlemen, thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Privia Health Fourth Quarter Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. If you would like to ask a question during th ...

This is my first cover of Nutex Health ( NUTX ). In this article, I will describe their business, and the recent developments. I will talk about how the issue of insurers not paying providersI first entered investing in 2016 as an individual value investor. In 2022, I established the investment firm Libra Capital. I mostly write articles as part of my deep research into a company before I make an investment, whether long or short. For me, a ''hold'' article means neutral; don't touch the stock and exit a po ...

Williams also addressed CMS’s Medicare Advantage (MA) Advance Notice for 2027, saying the proposal “does not sufficiently reflect” rising costs and utilization from chronic disease and an aging Medicare population. He said the company expects the impact of the risk model revision and normalization described in the Advance Notice to be “generally in line with the national average,” and argued that agilon’s burden of illness and clinical pathway programs can help mitigate risk model impacts, as they did durin ...